Amgen (AMGN) investor relations material

Business performance and financial highlights

• Achieved over $10 billion in quarterly revenue, up 10% year-on-year, with 22 products delivering double-digit sales growth.

• Six key growth drivers grew 26% year-on-year, representing nearly 70% of product sales.

• Maintained strong margins and earnings while increasing investment in innovation.

• Focus remains on cash-on-cash returns and disciplined capital allocation to enable commercial and pipeline growth.

• Capital deployment prioritizes funding innovation, commercial expansion, and manufacturing, with a focus on high-return opportunities both internally and externally.

Pipeline and clinical development updates

• Landmark phase III results for IMDELLTRA in small-cell lung cancer showed significant survival benefits, supporting its advancement as a foundational therapy.

• FDA approved a label update for IMDELLTRA, reducing monitoring time for initial doses and simplifying patient care.

• Positive phase III data for TEZSPIRE in eosinophilic esophagitis and TEPEZZA in chronic thyroid eye disease were announced.

• Late-stage pipeline includes MariTide, dazodalibep, and xaluritamig, all in phase III, targeting significant unmet needs.

• Olpasiran continues development for cardiovascular risk reduction, with attention on competitor data to inform future strategy.

Biosimilars and regulatory progress

• Advancing biosimilar candidates to KEYTRUDA, OPDIVO, OCREVUS, and EYLEA HD, with ABP 234 meeting endpoints and ABP 206 under FDA review.

• Regulatory submissions for biosimilars planned for the second half of the year, with FDA action expected by year-end.